Repurposing FDA Approved Drugs for Psoriasis Indications Through Integrated Molecular Docking, One-SVM Algorithm, and Molecular Dynamics Simulation Approaches

The study aimed to identify FDA-approved drugs that could be repurposed as treatments for psoriasis, a condition with unclear causes and no permanent cure. Current biologics for psoriasis are costly and pose risks of serious infections, especially in patients with tuberculosis and cardiovascular disorders. By analyzing drug-target interactions from databases for 19 autoimmune diseases and other conditions, the researchers used molecular docking, one-SVM algorithm prediction, and molecular dynamics simulation to evaluate potential anti-psoriasis drugs. The study identified Pioglitazone, Trimipramine, and Dimetindene as the top three candidates for repurposing as psoriasis treatments.